This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Lise Loberg, PhD
Senior Principal Research Scientist, Emerging Technology Platforms at AbbVie


Dr. Loberg has 20 years’ experience in the biopharmaceutical industry.  Currently she is Scientific Director in Emerging Therapeutic Platforms where she manages teams in preclinical safety, drug metabolism and pharmacokinetics, process chemistry, and formulations development to advance novel technical platforms from discovery to development.  Prior to this role, she led preclinical safety development of oncology antibody-drug conjugates (ADC). Dr. Loberg has supported preclinical safety evaluation of small and large molecule compounds across all stages of development and ranging across several therapeutic areas. Dr. Loberg earned her Ph.D. in Toxicology from University of Cincinnati and worked at IIT Research Institute before joining Abbvie.

Agenda Sessions

  • Preclinical Safety Evaluation for ADCs: Strategy and Risk Assessment